Propanc Biopharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, with fiscal 2022 comparative figures. The request identifies “2022 Q4,” but this filing is an annual report for FY2023, not a quarterly report. Financial amounts below are U.S. dollars unless noted.
Business context
Propanc is a pre-revenue biopharmaceutical company developing PRP, an intravenous formulation of pancreatic proenzymes, for solid tumors, initially targeting advanced pancreatic and ovarian cancers. PRP remains preclinical; the company reports no product sales. Its POP1 research program is developing recombinant versions of the proenzymes. The company reported FDA orphan drug designation for PRP in pancreatic cancer. Its prior human data described in the filing concern a small study of a rectal proenzyme formulation, not a Phase I trial of intravenous PRP.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,776,645 | $1,990,870 |
| Operating loss | ($1,776,645) | ($1,990,870) |
| Interest expense | $532,821 | $568,798 |
| Loss from change in fair value of derivative liabilities | ($530,330) | ($99,111) |
| Net loss | ($2,660,566) | ($2,658,087) |
| Net cash used in operating activities | ($1,105,251) | ($1,436,304) |
| Net cash provided by financing activities | $1,113,719 | $1,490,786 |
| Cash at year-end | $10,047 | $4,067 |
Gross and operating margins are not meaningful because the company had no revenue. FY2023 R&D expense was $247,919, down from $256,052. Administration expense fell to $1,499,885 from $1,706,452, largely due to lower stock-based and consulting-related expense. Net loss was broadly unchanged; the larger derivative-liability valuation loss offset some operating-expense reductions. The Australian R&D tax credit was $129,841, compared with $54,977 in FY2022.
At June 30, 2023, total assets were $60,328 and total liabilities were $3,177,507, including current liabilities of $3,158,229. Current liabilities included $390,539 of convertible notes, net of discounts and including put premiums; $65,280 of loan payable; $423,209 of embedded conversion-option liabilities; and substantial accounts payable, accrued expenses and employee-benefit liabilities. Working-capital deficit was $3,139,190; stockholders’ deficit was $3,117,179; accumulated deficit was $64,684,732. Cash was insufficient to meet obligations for the next 12 months, according to management.
Cash from financing in FY2023 included $590,250 of convertible-note proceeds and $475,000 from warrant exercises. Financing proceeds were lower than in FY2022. The filing states that operations depend on additional debt or equity financing and that failure to obtain funding could force the company to curtail operations.
Material changes, outlook and risks
- Shares outstanding increased substantially through debt conversions and other issuances. The company reported 6,031,250 shares issued at June 30, 2023 and 14,833,210 issued and outstanding at September 27, 2023. A 1-for-1,000 reverse stock split took effect May 1, 2023; reported share and per-share data were retrospectively adjusted where applicable.
- Many financing instruments carry variable or discounted conversion prices, default-rate increases, repayment premiums and share-reserve requirements. These terms create dilution and repayment risk. After year-end, a related-party lender provided a three-year AU$230,000 loan at 10% and received warrants for 15 million shares at an initial $0.01 exercise price. The company also disclosed additional short-term and convertible borrowings and a proposed equity line of up to $5 million, subject to conditions and registration effectiveness.
- Management’s stated plan was to submit a clinical trial application and begin a Phase Ib study in advanced solid-tumor patients, with first patient/first visit targeted for June 2024 and estimated study costs of approximately $6.5 million. These were plans stated in the filing, not achieved milestones; additional financing and regulatory approvals are required. Management estimated three to four years to a Phase IIa proof-of-concept milestone, subject to approvals, R&D results and licensing activity.
- The company reports preclinical findings and limited prior human observations, but PRP’s safety and efficacy remain unproven in clinical trials. Development, manufacturing, regulatory approval, patent protection, reimbursement and commercialization are uncertain; competitors may have substantially greater resources.
- The auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. The statements include no adjustments for the possible outcome of that uncertainty.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at June 30, 2023, citing undocumented controls, inadequate segregation of duties, no audit committee, and insufficient financial-reporting review and U.S. GAAP expertise. Remediation depends partly on obtaining capital.
- Other notable items include $466,273 of deemed dividends from warrant down-round features; $30,000 of IRS penalties plus accrued interest for late historical Form 5471 filings, already accrued; related-party office leasing and management compensation; and no material litigation reported.
Most important facts for investors to verify
- Current cash, upcoming maturities, defaults and whether financing sufficient for operations and the proposed clinical program has actually been secured.
- Updated share count, remaining conversion and warrant reserves, effective conversion terms, and potential dilution from outstanding or subsequent financing.
- Whether the clinical trial application was submitted and approved, whether the Phase Ib study began, and whether the stated $6.5 million estimate remains current.
- Clinical evidence supporting PRP specifically, including study design, formulation and route of administration; distinguish preclinical results and prior suppository observations from clinical evidence for intravenous PRP.
- Progress in remediating the disclosed material weaknesses and the status of the going-concern risk.